Mei-mei Zheng

Guangzhou, 510080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.

Journal: Science translational medicine

Published: August 26, 2026

Current and future immunotherapies for NSCLC.

Current and future immunotherapies for NSCLC.

Journal: Journal of hematology & oncology

Published: December 23, 2025

LAMPAD: An Integrated Circulating Tumor DNA-Based Model for Predicting Potential Cure in Patients With Resected NSCLC.

LAMPAD: An Integrated Circulating Tumor DNA-Based Model for Predicting Potential Cure in Patients With Resected NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 21, 2025

Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases.

Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases.

Journal: Journal for immunotherapy of cancer

Published: October 26, 2025

Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer.

Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer.

Journal: Nature reviews. Clinical oncology

Published: May 05, 2025

First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial.

First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 12, 2024

Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report.

Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report.

Journal: Translational lung cancer research

Published: October 17, 2024

Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma.

Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma.

Journal: JTO clinical and research reports

Published: March 21, 2024

"Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC.

"Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 04, 2024

Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases.

Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases.

Journal: Nature medicine

Published: November 17, 2023

Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.

Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.

Journal: Cell reports

Published: August 21, 2023

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.

Journal: EClinicalMedicine

Published: July 30, 2023

Showing 1-12 of 25

Last Updated: 09/26/2026